Michael Cheng, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Memorial Sloan Kettering Cancer CenterMedical Oncology
    University of California, San FranciscoInternal Medicine
    University of California, Los AngelesMDMedicine
    University of California, BerkeleyBAMolecular and Cell Biology
    Collapse Awards and Honors
    Conquer Cancer Foundation of ASCO Career Development Award
    PCF Young Investigator Award
    Conquer Cancer Foundation of ASCO Merit Award
    Alpha Omega Alpha
    Phi Beta Kappa

    Collapse Overview 
    Collapse Overview
    Dr. Michael L. Cheng is an academic medical oncologist and Assistant Professor at the University of California, San Francisco (UCSF), where he leads clinical and translational research focused on advancing discoveries in cancer genomics and developing improved therapies for thoracic malignancies, especially Non-Small Cell Lung Cancer (NSCLC). Dr. Cheng received his M.D. from the UCLA David Geffen School of Medicine, where he graduated with Alpha Omega Alpha honors. He completed his residency in Internal Medicine at UCSF and his fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. Prior to returning to UCSF, Dr. Cheng was an Assistant Professor at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Cheng strives to provide individualized, compassionate care with a focus on precision oncology, and continues to be inspired by the tangible and substantial patient benefit driven by research advances. Dr. Cheng sees patients at UCSF Health, and his clinic is located in the Bakar Precision Cancer Medicine Building on the UCSF Mission Bay campus.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023 Aug 24; 389(8):710-721. Sacher A, LoRusso P, Patel MR, Miller WH, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J, GO42144 Investigator and Study Group. PMID: 37611121.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 07 05; 29(13):2540-2550. Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, Shapiro GI, Park H, Nishino M, Lindsay J, Felt KD, Sharma B, Cherniack AD, Rodig S, Gomez DR, Shaverdian N, Rakaee M, Bandlamudi C, Ladanyi M, Janne PA, Schoenfeld AJ, Sholl LM, Awad MM, Cheng ML. PMID: 37097610.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO Precis Oncol. 2023 Jun; 7:e2200633. Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Jänne PA, Coker S, Diamond JR, Hilton J, Shapiro GI, French CA. PMID: 37384867.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022 11; 6:e2200382. Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, Jänne PA. PMID: 36455195.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Cancers (Basel). 2022 Aug 23; 14(17). Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, Ünsal-Kaçmaz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR. PMID: 36077617; PMCID: PMC9454848.
      View in: PubMed   Mentions: 4  
    6. Lipid pneumonia associated with mineral oil use presenting as fluorine-18-fluorodeoxy-D-glucose-avid lung mass. JTCVS Tech. 2022 Oct; 15:192-194. Cheng ML, Thomas V, Vaz N, Hammer MM, Nishino M, Vargas SO, Khalil HA. PMID: 36276695; PMCID: PMC9579874.
      View in: PubMed   Mentions:
    7. Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505. French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI. PMID: 35417004; PMCID: PMC9197941.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    8. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. JTO Clin Res Rep. 2022 Jul; 3(7):100347. Schneider JL, Muzikansky A, Lin JJ, Krueger EA, Lennes IT, Jacobson JO, Cheng M, Heist RS, Piotrowska Z, Gainor JF, Shaw AT, Dagogo-Jack I. PMID: 35815322; PMCID: PMC9257415.
      View in: PubMed   Mentions: 1  
    9. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO Precis Oncol. 2021 11; 5:726-732. Cheng ML, Milan MSD, Tamen RM, Bertram AA, Michael KS, Ricciuti B, Kehl KL, Awad MM, Sholl LM, Paweletz CP, Jänne PA. PMID: 34994618.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. The immune niche of the liver. Clin Sci (Lond). 2021 10 29; 135(20):2445-2466. Cheng ML, Nakib D, Perciani CT, MacParland SA. PMID: 34709406.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    11. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. J Thorac Oncol. 2021 07; 16(7):1176-1187. Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. PMID: 33845210.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    12. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Med. 2021 05 31; 13(1):96. Tsui DWY, Cheng ML, Shady M, Yang JL, Stephens D, Won H, Srinivasan P, Huberman K, Meng F, Jing X, Patel J, Hasan M, Johnson I, Gedvilaite E, Houck-Loomis B, Socci ND, Selcuklu SD, Seshan VE, Zhang H, Chakravarty D, Zehir A, Benayed R, Arcila M, Ladanyi M, Funt SA, Feldman DR, Li BT, Razavi P, Rosenberg J, Bajorin D, Iyer G, Abida W, Scher HI, Rathkopf D, Viale A, Berger MF, Solit DB. PMID: 34059130; PMCID: PMC8165771.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    13. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021 03; 9(3). Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M. PMID: 33771889; PMCID: PMC7996662.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    14. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO Precis Oncol. 2021; 5. Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, Jänne PA, Oxnard GR, Paweletz CP. PMID: 34250387; PMCID: PMC8232122.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    15. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA Cancer J Clin. 2021 03; 71(2):176-190. Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. PMID: 33165928.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    16. Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precis Oncol. 2020; 4. Cheng ML, Donoghue MTA, Audenet F, Wong NC, Pietzak EJ, Bielski CM, Isharwal S, Iyer G, Funt S, Bagrodia A, Bajorin DF, Reuter VE, Eng J, Joseph G, Bourque C, Bromberg M, Ling L, Selcuklu SD, Arcila ME, Tsui DWY, Zehir A, Viale A, Berger MF, Bosl GJ, Sheinfeld J, Van Allen E, Taylor BS, Al-Ahmadie H, Solit DB, Feldman DR. PMID: 33163850; PMCID: PMC7608584.
      View in: PubMed   Mentions: 6     Fields:    
    17. Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. JCO Precis Oncol. 2020; 4. Lee Y, Clark EW, Milan MSD, Champagne C, Michael KS, Awad MM, Barbie DA, Cheng ML, Kehl KL, Marcoux JP, Rabin MS, Rotow JK, Sands JM, Jänne PA, Oxnard GR. PMID: 33015530; PMCID: PMC7529535.
      View in: PubMed   Mentions: 5     Fields:    
    18. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4135-4142. Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. PMID: 32332016.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    19. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma Res. 2020 02; 30(1):71-75. Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD. PMID: 31425479; PMCID: PMC7485135.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    20. Author Correction: Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2020 01; 577(7789):E1. Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. PMID: 31822847.
      View in: PubMed   Mentions:    Fields:    
    21. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer. 2020 02; 140:35-41. Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, Jänne PA, Kuo FC, Oxnard GR, Sholl LM. PMID: 31855703.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    22. Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019 07; 571(7766):576-579. Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. PMID: 31292550; PMCID: PMC7048239.
      View in: PubMed   Mentions: 159     Fields:    Translation:HumansCells
    23. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019 Apr 01; 5(4):471-478. Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. PMID: 30589920; PMCID: PMC6459218.
      View in: PubMed   Mentions: 218     Fields:    Translation:HumansCells
    24. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018 09 10; 34(3):427-438.e6. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. PMID: 30205045; PMCID: PMC6327853.
      View in: PubMed   Mentions: 375     Fields:    Translation:HumansCells
    25. Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC? Clin Cancer Res. 2019 02 01; 25(3):899-900. Cheng ML, Oxnard GR. PMID: 30190372; PMCID: PMC6359945.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    26. Clinical tumour sequencing for precision oncology: time for a universal strategy. Nat Rev Cancer. 2018 09; 18(9):527-528. Cheng ML, Berger MF, Hyman DM, Solit DB. PMID: 30030494; PMCID: PMC6618305.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    27. Novel biomarkers in bladder cancer. Urol Oncol. 2018 03; 36(3):115-119. Cheng ML, Iyer G. PMID: 29472156.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    28. Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care. Ann Intern Med. 2018 02 06; 168(3):221-222. Cheng ML, Solit DB. PMID: 29310131; PMCID: PMC6659420.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? Cancer Epidemiol. 2015 Apr; 39(2):143-9. Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K. PMID: 25662402; PMCID: PMC4470609.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    30. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol. 2014 Mar; 15(1):115-26. Cheng ML, Fong L. PMID: 24402184; PMCID: PMC4523381.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    31. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol. 2014 Jan 07; 3:329. Cheng ML, Fong L. PMID: 24432249; PMCID: PMC3882875.
      View in: PubMed   Mentions: 40  
    32. Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother. 2013 Jan; 14(1):91-6. Ryan CJ, Cheng ML. PMID: 23199349.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    33. Coccidioidal endophthalmitis in immunocompetent person, California, USA. Emerg Infect Dis. 2012 Jun; 18(6):1015-6. Cheng ML, Leibowitz M, Ha E. PMID: 22608196; PMCID: PMC3358163.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals